ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Jp2011, analyst have raised the consensus earnings estimates over Q2's consensus estimates. This is line with ANIP raising guidance, they may however be using the low end in ANIP's guidance of $425 million. If so, then ANIP would only average $100.85 million over the next two quarters. Even using the top guidance of $445 million. ANIP would average $110.85 million for Q3 and Q4. Below the $116.5 million in revenue of Q2. They are also likely projecting Q3 will be lower than Q4, as consortiums will most likely make larger purchases in Q4 to take advantage of the lower price over 2024 prices.

I think it will be moot. As ANIP should easily beat estimates.

JMHO